Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 19 - Drugs for skeletal disorders
Patents for A61P 19 - Drugs for skeletal disorders (81,981)
12/2003
12/18/2003US20030232865 1,4-Benzofused urea compounds useful in treating cytokine mediated diseases
12/18/2003US20030232864 Novel Compounds and compositions as protease inhibitors
12/18/2003US20030232863 Cathepsin cysteine protease inhibitors
12/18/2003US20030232859 Antiinflammatory agents; for treatment of rheumatoid arthritis and multiple sclerosis
12/18/2003US20030232846 Caspase inhibitors and uses thereof
12/18/2003US20030232844 Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2 mediated disorders
12/18/2003US20030232831 Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
12/18/2003US20030232823 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof
12/18/2003US20030232815 Non-peptidic cyclophilin binding compounds and their use
12/18/2003US20030232813 Novel amino substituted pyrimidinone derivatives
12/18/2003US20030232805 Administering a dual serotonin/norepinephrine reuptake inhibitor or a triple monoamine reuptake inhibitor for serotonin/noradrenaline/ dopamine
12/18/2003US20030232788 Inhibitors of interleukin-1 beta converting enzyme and related proteases
12/18/2003US20030232784 Pyridine manganese amine complex macrocycle; treatment of rheumatoid arthritis
12/18/2003US20030232763 Reducing blood glucose concentrations, weight loss, and treating diseases and conditions mediated by the cyclooxygenase-2 and 5-lipoxygenase enzymes; an enzyme inhibitors
12/18/2003US20030232752 Proliferated cell lines and uses thereof
12/18/2003US20030232751 Administering calmodulin to prevent bone disorders characterized by decreased bone mass such as osteopenia and osteoporosis, as well as those suffering from non-union fractures
12/18/2003US20030232741 Methods of treatment of glaucoma and other conditions mediated by NOS-2 expression via inhibition of the EGFR pathway
12/18/2003US20030232349 Nucleic acid and amino acid sequences of proteases and the use of these sequences in the diagnosis and treatment of gastrointestinal, cardiovascular, autoimmune/inflammatory, cell proliferative, and neurological disorders
12/18/2003US20030232326 Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences
12/18/2003DE10215316C1 Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer Quinoline and isoquinoline derivatives, to a pharmaceutical agent and their use as anti-inflammatory agents
12/18/2003CA2493890A1 Methods for using adamts-12, an integrin and metalloprotease with thrombospondin motifs
12/18/2003CA2490037A1 Galactosyl isomalt, a method for producing it and its use
12/18/2003CA2488861A1 Use of orally-available prostacyclin derivatives for the production of a medicament for the treatment of disease states associated with bone marrow oedema
12/18/2003CA2488609A1 A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
12/18/2003CA2488602A1 Substituted pyrrolines as kinase inhibitors
12/18/2003CA2488567A1 (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents
12/18/2003CA2488403A1 Pharmaceutical formulation
12/18/2003CA2488402A1 Pyrazole-derivatives as p38 kinase inhibitors
12/18/2003CA2488227A1 Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
12/18/2003CA2488108A1 Liquid formulation of decitabine and use of the same
12/18/2003CA2487977A1 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
12/18/2003CA2487924A1 Use of corticotroph-derived glycoprotein hormone to treat inflammation and potentiate glucocorticoid action
12/18/2003CA2487900A1 Immunity-related protein kinase inhibitors
12/18/2003CA2487838A1 Methods and compounds for inhibiting the cytokine or biological activity of mif
12/18/2003CA2487428A1 Cd200-receptor mediated modulation of bone development
12/18/2003CA2487413A1 Methods of treating angiogenesis, tumor growth, and metastasis
12/18/2003CA2486491A1 4-(aryl or heteroaryl)-2-butylamine derivatives and their use as glucocorticoid ligans
12/18/2003CA2485874A1 T cell receptor cdr3 sequences and methods for detection
12/18/2003CA2483555A1 Gamma lactams as prostaglandin agonists and use thereof
12/17/2003EP1371650A1 Activator for peroxisome proliferator-activated receptor
12/17/2003EP1371646A1 Aryl-substituted alicyclic compound and medical composition comprising the same
12/17/2003EP1371372A1 Use of active substance mixtures containing tocopherols and harpagophytum procumbens extracts for the preparation of a drug against rheumatic arthritis
12/17/2003EP1370659A2 Proteins, polynucleotides encoding them and methods of using the same
12/17/2003EP1370647A2 A dna molecule encoding a variant paraoxonase and uses thereof
12/17/2003EP1370588A2 Human monoclonal antibodies to fc alpha receptor (cd89)
12/17/2003EP1370586A2 Nuclear hormone receptor ligand binding domain
12/17/2003EP1370584A2 Nuclear hormone receptor ligand binding domain
12/17/2003EP1370583A1 Polypeptides and nucleic acids for bolekine
12/17/2003EP1370579A1 Matrix gene expression in chondrogenesis
12/17/2003EP1370562A1 Thieno[2,3-d]pyrimidindione derivatives as matrix metalloproteinase inhibitors
12/17/2003EP1370560A1 Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists
12/17/2003EP1370559A1 Triazolopyridines as anti-inflammatory agents
12/17/2003EP1370556A1 Metalloproteinase inhibitors
12/17/2003EP1370554A1 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors
12/17/2003EP1370553A2 Rho-kinase inhibitors
12/17/2003EP1370552A2 Rho-kinase inhibitors
12/17/2003EP1370540A1 Anti-thrombotic carboxylic acid amides, the production thereof and use of the same as medicaments
12/17/2003EP1370538A1 Metalloproteinase inhibitors
12/17/2003EP1370537A1 Metalloproteinase inhibitors
12/17/2003EP1370536A1 Metalloproteinase inhibitors
12/17/2003EP1370535A1 Metalloproteinase inhibitors
12/17/2003EP1370534A1 Metalloproteinase inhibitors
12/17/2003EP1370531A1 Phenylalanine enamide derivatives possessing a cyclobutene group, for use as integrin inhibitors
12/17/2003EP1370530A1 Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical
12/17/2003EP1370518A2 Tryptase-inhibitors
12/17/2003EP1370287A2 Method and composition for modulating bone growth
12/17/2003EP1370279A2 Use of the long pentraxin ptx3 for the preparation of medicament for the prevention and cure of autoimmune pathologies
12/17/2003EP1370276A2 Medical uses of intercellular communication facilitating compounds
12/17/2003EP1370266A1 Method of treatment
12/17/2003EP1370257A1 Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids
12/17/2003EP1370256A1 Novel inhibitors of formation of advanced glycation endproducts (ages)
12/17/2003EP1370250A2 Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
12/17/2003EP1370211A2 Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
12/17/2003EP1206467B1 N-heterocyclic derivatives as nos inhibitors
12/17/2003EP0984981B1 Anti-inflammatory tyrosine derivatives
12/17/2003EP0954580B1 Human sdf-5 protein and compositions
12/17/2003CN1462276A Peptide-based compounds
12/17/2003CN1462195A Pharmaceutical compositions comprising dendritic cells for immunotherapy of automimmune disease and treatment methods using the same
12/17/2003CN1131309C IL-6 mutein
12/17/2003CN1131241C Cross-linked hyaluronic acids and medical uses thereof
12/17/2003CN1131051C Medicine for treating cervical vertebra disease and preparation process
12/17/2003CN1131047C Ointment for treating spinal hyperosteogeny
12/17/2003CN1131041C Preparing process for instant aminoacid-calcium particles
12/16/2003US6664256 Interleukin- 1 beta inhibitors
12/16/2003US6664247 Pyrazole compounds useful as protein kinase inhibitors
12/16/2003US6664230 Orally administered peptides to ameliorate atherosclerosis
12/16/2003US6664229 Methods for treatment using novel ligands of the neuropeptide receptor HFGAN72
12/16/2003US6664227 Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
12/11/2003WO2003102237A1 Treatment with cytokines
12/11/2003WO2003102230A1 Pthrp-based prediction and diagnosis of bone disease
12/11/2003WO2003102183A1 Pramyxovirus vectors encoding antibody and utilization thereof
12/11/2003WO2003102180A1 NOVEL PEPTIDES HAVING cAMP PRODUCING ACTIVITY
12/11/2003WO2003102138A2 Elongase genes and uses thereof
12/11/2003WO2003101989A1 Inhibitors of jak and cdk2 protein kinases
12/11/2003WO2003101981A1 Novel substituted indoles
12/11/2003WO2003101980A1 1,3,5-triazine derivatives as ligands for human adenosine-a3 receptors
12/11/2003WO2003101978A1 Phenyl-thiophene type vitamin d receptor modulators
12/11/2003WO2003101964A1 Piperidine derivative, process for producing the same, and use
12/11/2003WO2003101959A1 Pyrrole compounds for the treatment of prostaglandin mediated diseases
12/11/2003WO2003101958A2 Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors
1 ... 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 ... 820